纽约市结核性脑膜炎患者长期死亡率:队列研究
该回顾性队列研究纳入1992至2001年纽约市324例培养确诊的结核性脑膜炎患者,分析耐药与10年死亡率的关系。结果显示,在无利福平耐药的患者中,异烟肼耐药与治疗60天后死亡独立相关(校正风险比1.94,95%CI 1.08-3.94);利福平耐药患者中94%(63/67)在完成抗结核治疗前死亡。
要点
- 异烟肼耐药与治疗60天后死亡独立相关(aHR 1.94,95%CI 1.08-3.94)。
- 利福平耐药患者早期死亡率高,94%(63/67)未完成治疗即死亡。
- 建议对临床疑似耐药结核性脑膜炎患者经验性加用二线药物。
核心结论
- 培养确诊的结核性脑膜炎患者中,利福平耐药者早期死亡迅速,异烟肼耐药与治疗60天后死亡独立相关。
研究设计与样本
- 回顾性队列研究,纳入1992年1月1日至2001年12月31日纽约市结核病登记中324例培养确诊、有利福平和异烟肼药敏结果、且至少开始2种抗结核药物治疗的结核性脑膜炎患者。
主要发现
- 在257例无利福平耐药菌株的结核性脑膜炎患者中,控制年龄和HIV感染后,异烟肼耐药与治疗60天后死亡相关(校正风险比1.94,95%CI 1.08-3.94)。
- 67例利福平耐药结核性脑膜炎患者中,63例(94%)在完成抗结核治疗前死亡。
临床怎么用
- 对临床疑似耐药结核性脑膜炎患者,应继续评估快速诊断技术并经验性加用二线抗结核药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculous meningitis (TBM) is the most devastating clinical presentation of infection with Mycobacterium tuberculosis; delayed initiation of effective antituberculosis therapy is associated with poor treatment outcomes. Our objective was to determine the relationship between drug resistance and 10-year mortality among patients with TBM. METHODS: We conducted a retrospective cohort study of 324 patients with culture-confirmed TBM, susceptibility results reported for isoniazid and rifampin, and initiation of at least 2 antituberculosis drugs, reported to the tuberculosis registry in New York City between 1 January 1992 and 31 December 2001. Date of death was ascertained by matching the tuberculosis registry with death certificate data for 1992-2012 from the New York Office of Vital Statistics. Human immunodeficiency virus (HIV) status was ascertained by medical records review, matching with the New York City HIV Surveillance registry, and review of cause of death. RESULTS: Among 257 TBM patients without rifampin-resistant isolates, isoniazid resistance was associated with mortality after the first 60 days of treatment when controlling for age and HIV infection (adjusted hazard ratio, 1.94 [95% confidence interval, 1.08-3.94]). Death occurred before completion of antituberculosis therapy in 63 of 67 TBM patients (94%) with rifampin-resistant disease. CONCLUSIONS: Among patients with culture-confirmed TBM, we observed rapid early mortality in patients with rifampin-resistant isolates, and an independent association between isoniazid-resistant isolates and death after 60 days of therapy. These findings support the continued evaluation of rapid diagnostic techniques and the empiric addition of second-line drugs for patients with clinically suspected drug-resistant TBM.
引用
- Vinnard C, King L, Munsiff S, et al. Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study. Clin Infect Dis. 2017. PMID: 27927856. doi:10.1093/cid/ciw763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。